<DOC>
	<DOCNO>NCT00413088</DOCNO>
	<brief_summary>Open pharmacokinetic study 5 parallel group two treatment phase ( bemiparin 3,500 IU multiple dose bemiparin 115 IU/kg single dose ) . The bemiparin pharmacokinetic profile assess measure effect coagulation cascade . Plasma anti-Xa activity ( measure use chromogenic amidolytic assay ) IU per milliliter primary endpoint ass pharmacokinetic profile bemiparin .</brief_summary>
	<brief_title>Study Assess Bemiparin Pharmacokinetics Renal Insufficiency Elderly</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Nonelderly healthy volunteer ( Group I ) : Male female subject age 18 65 year body weight , clinical history , physical examination , vital sign ( systolic diastolic blood pressure , heart beat rate body temperature ) , ECG laboratory test ( hemogram biochemistry ) within normal range without evidence significant organic psychiatric illness accept participate study sign write informed consent . Patients renal insufficiency ( Groups II , III IV ) : Male female subject age 18 65 year , assign one follow group accord renal function : Group II : mild renal insufficiency ( creatinine clearance &gt; 50 80 ml/min ) ; Group III : Moderate renal insufficiency ( creatinine clearance : 30 50 ml/min ) ; Group IV : Severe renal insufficiency ( creatinine clearance &lt; 30 ml/min ) . The degree renal insufficiency calculate basis determination creatinine clearance measure total urinary output 24h period serum creatinine level . Urine sample collect 2 week first experimental period . Patients renal insufficiency must stable renal function 3 month inclusion study . They must body weight 45 110 Kg . They accept participate study sign write informed consent . Elderly healthy volunteer ( Group V ) : Male female subject age &gt; 65 year old fulfill remain inclusion criterion specify nonelderly healthy volunteer . Nonelderly healthy volunteer ( Group I ) : Previous history alcoholism drug consumption Important consumer excite drink Hypersensitivity , allergy , idiosyncrasy medicine Taking another medication four week initiation trial include medication without prescription medicinal plant Positive serology hepatitis B , C HIV virus History clinic evidence concomitant disease Familiar history coagulation 's disorder surgery within previous 6 month Women pregnant use effective contra conceptive method Ethanol , cannabis , cocaine , amphetamine , benzodiazepin opiate urine Current platelet count &lt; 100.000/mm3 serum K &gt; 5,5 mEq/L Any contraindication bemiparin administration order authorize summary product characteristic Healthy volunteer participate another clinical trial do past 2 month To give blood four week begin trial Patients renal insufficiency elderly healthy volunteer ( Groups II , III , IV , V ) : Previous history alcoholism drug consumption Important consumer excite drink Hypersensitivity , allergy , idiosyncrasy medicine Treatment enzymatic inhibitor inductor medicine Administration ASA dosis &gt; 125 mg/day and/or NDAIs halflife &gt; 20 hour high antiagregant effect previous ten day inclusion Chronic hepatopatology bilirubin level &gt; 1,5 mg/dl and/or increment AST/ALT level twice high maximum limit normality prothrombin time 20 % high maximun limit normality haemoglobine &lt; 8gr/dl albumim level &lt; 3gr/dl Previous history acute infarction myocardium , cardiac ischemic arrhythmia Acute illness previous week participation Familiar history coagulation 's disorder surgery within previous 6 month Women pregnant use effective contra conceptive method Ethanol , cannabis , cocaine , amphetamine , benzodiazepin opiate urine Current platelet count &lt; 75.000/mm3 serum K &gt; 6 mEq/L Any contraindication bemiparin administration order authorize summary product characteristic Healthy volunteer participate another clinical trial do past 2 month To give blood four week begin trial Subjects haemodialysis peritoneal dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>renal insufficency</keyword>
	<keyword>low molecular weight heparin</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>elderly</keyword>
</DOC>